Structure (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 01)
Duloxetine Capsule, Delayed Release
Product Images NDC 70518-4440
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 70518-4440). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 02)
This text provides data on the proportion of patients with relapse over time when treated with a placebo versus duloxetine. The graph displays the time from randomization to relapse (in days) using the Kaplan-Meier estimator method. The information indicates that the number of patients experiencing relapse decreases over time under both treatments.*
Figure 2 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 03)
This text provides information about the percentage of patients experiencing a relapse over time under two different treatments: placebo and duloxetine. The data is shown graphically with days to relapse on the x-axis and the proportion of patients on the y-axis. The Kaplan-Meier estimator method was used to calculate these proportions.*
Figure 1 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 04)
This text provides information on the percentage of patients who improved based on different treatments such as Duloxetine 60mg, Duloxetine 20mg, and placebo in terms of pain relief. It indicates the effectiveness of different dosages of Duloxetine in managing pain.*
Figure 2 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 05)
Fig 5 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 06)
Percentage of Patients Improved in terms of pain management with Duloxetine 60 mg twice daily compared to Duloxetine 60 mg once daily and Placebo. The chart shows the percent improvement in pain from baseline for different levels of pain improvement.*
Fig 6 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 07)
This text provides information on the percentage of patients improved in a clinical study involving different dosages of Duloxetine and a placebo. The chart shows the percentage improvement in pain from baseline for each treatment group. The data suggests the effectiveness of Duloxetine in improving pain symptoms compared to a placebo.*
Fig 7 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 08)
This is a data table showing the percentage of pediatric patients aged 13 to 17 years old with Juvenile Fibromyalgia Syndrome achieving various levels of pain relief at week 12 in Study FM-4. The table compares the percentage of patients improved on Duloxetine 60mg Once Daily versus Placebo. The percentage of pain relief from baseline is also indicated, with pain relief measured by the Brief Pain Inventory - Modified Short Form: Adolescent Version Average Pain Score. Duloxetine-treated patients started with 30mg once daily for 1 week and then increased to 60mg once daily for 12 weeks.*
Figure 8 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 09)
This text provides data on the percentage of patients improved with Placebo and Duloxetine (60/120 mg once daily). It also includes a graphical representation of percent improvement in pain from baseline (BOCF).*
Figure 9 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 10)
This text provides data on the percentage of patients improved with Duloxetine 60 mg compared to a placebo. The graph displays the percentage improvement in pain from baseline with Duloxetine 60 mg once daily. The data indicates a significant improvement in pain for patients taking Duloxetine 60 mg compared to a placebo.*
Figure 10 (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 11)
This text provides information about the percentage of patients improved with Duloxetine 60/120 mg compared to placebo in a study. The chart shows percentages ranging from 10% to 90% for pain improvement from baseline. Baseline Observation Carried Forward (BOCF) method for analysis is also mentioned.*
Remedy_label (Remedy Label)
This is a description of Duloxetine Capsule, a delayed-release medication in 20 mg strength with a quantity of 30 capsules. The capsule is green with marking LU.Q01. It provides information such as NDC number, expiration date, manufacturer details (Lupin Pharma from Baltimore, MD), and storage instructions. The text also mentions dosage details to be found in the insert and the importance of keeping the medication away from children. It is repackaged by RemedyRepack Inc. in Indiana, PA.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
